LDS/Medical Tests/Maternal Serum Screen (Quad Screen), Second Trimester

Maternal Serum Screen (Quad Screen), Second Trimester

Maternal serum screening is performed as a prenatal screening test to assist in the identification of fetal development with increased risk of certain birth defects, including open neural tube defects (NTD) such as spina bifida and anencephaly, and chromosomal disorders such as Down syndrome and Trisomy 18. Screening tests are designed to identify those individuals with increased risk who might benefit from additional diagnostic testing, but is not diagnostic in itself. Risk assessment for neural tube defect is based on alpha-fetoprotein (AFP) alone, whereas Down syndrome and Trisomy 18 risk assessments are based on multiple marker combinations that include AFP, total beta-human chorionic gonadotropin (hCG), unconjugated Estriol (uE3) (collectively a “triple screen”), and inhibin A (collectively a “quad screen”).

Quantitative alpha-fetoprotein concentrations are correlated with an increased risk of a baby having neural tube defect if increased, and if decreased, are correlated with an increased risk of Down syndrome. Maternal beta-hCG is elevated in pregnancies where the fetus has Down syndrome. Decreased levels of uE3 and AFP are associated with Down syndrome and Trisomy 18. The addition of inhibin A appears to make the test more accurate in detecting pregnancies at risk of Down syndrome. During the pregnancy, inhibin A is secreted from both the corpus luteum and the placenta. In Down syndrome pregnancies, inhibin A levels are two-fold greater than in unaffected pregnancies, leading to the detection of approximately 40% of Down syndrome fetuses with a 5% false positive rate. However, when combined with maternal AFP, hCG and uE3, the detection rate increases to approximately 75%. Addition of inhibin A improves the detection rate by approximately 10% relative to commonly used marker combinations.

Multiple marker screening is typically performed at 15-17 weeks gestation, although it can be performed at 14-22 weeks gestation, if necessary.

  • Prenatal risk assessment for neural tube defect
  • Prenatal risk assessment for Down syndrome (Trisomy 21)
  • Prenatal risk assessment for Edwards syndrome (Trisomy 18)

For interpretation of results, pre-analytical information provided by patient’s clinician is crucial to calculate risk. See below for mandatory supplemental clinical information required from the clinician.

Serum concentrations of AFP, beta-hCG, uE3, and inhibin A are determined using the analytical methods stated below. The multiple of the median (MoM) is calculated for each and is specific for each week gestation. Different MoM values are used for African American and Asian populations. MoM values for all analytes are adjusted for maternal weight; however, only the AFP MoM is adjusted for insulin dependent diabetes status. All four MoM values are combined with maternal age at time of delivery to determine the Down syndrome risk. Trisomy 18 risk is based on maternal age and AFP, hCG, and uE3 MoMs. Neural tube defect risk is based on the AFP MoM only.

Note: The following patient information MUST be provided for accurate interpretation of results:

  1. Maternal date of birth (mm/dd/yy)
  2. Weight
  3. Race
  4. Number of fetuses
  5. Insulin-dependent diabetic status
  6. Estimated date of delivery as determined by ultrasound, LMP, or physical exam

Risk calculation is increased in:

  • Down syndrome
  • Trisomy 18
  • Open Spina Bifida
  • Anencephaly

Normal or decreased:

  • Non-pregnant women
Birth Defect (Disorder) Normal Risk Increased Risk
Open neural tube defect - -
Singleton Pregnancy AFP MoM < 2.5 AFP MoM ≥ 2.5
Twin Pregnancy AFP MoM < 4.0 AFP MoM ≥ 4.0
Insulin-dependent diabetic AFP MoM < 1.9 AFP MoM ≥ 1.9
Down syndrome Risk < 1:270 Risk ≥ 1:270
Trisomy 18 Risk < 1:100 Risk ≥ 1:100

For risk calculation and interpretation, special software takes the analytical result of testing and clinical information and calculates—through artificial intelligence algorithms—the risk and MoMs for each clinical presentation.

AFP: Immunochemiluminescence assay hCG: Immunochemiluminescence assay uE3: Immunochemiluminescence assay Inhibin A: Enzyme Immunoassay

Serum

Serum Red top preferred. Serum gel(SST) acceptable. 1.0 mL minimum. Do not draw after amniocentesis.

Stability

  • Ambient: 48 hours
  • Refrigerated: 7 days
  • Frozen: 90 days

SPECIAL INSTRUCTIONS: Must include: Gestational age, LMP, Weight, Race, Insulin dependent, number of fetuses, and initial or repeat screen.

Chromosomal analysis from amniocentesis or chorionic villi using cytogenetics or FISH (only if screening positive).
1-4 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Aust Fam Physician. 2011 Oct;40(10):785-7. [PMID: 2203480]
  • Canick JA, MacRae AR. Second trimester serum markers. Semin Perinatol. 2005 Aug;29(4):203-8. Review.
  • Cleary-Goldman J, Morgan MA, Malone FD, Robinson JN, D'Alton ME, Schulkin J. Screening for Down syndrome: practice patterns and knowledge of obstetricians and gynecologists. Obstet Gynecol. 2006 Jan;107(1):11-7.
  • Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. Lancet. 2003 Mar 8;361(9360):835-6.
  • Renier MA, Vereecken A, Van Herck E, Straetmans D, Ramaekers P, Buytaert P. Second trimester maternal dimeric inhibin-A in the multiple-marker screening test for Down's syndrome. Hum Reprod. 1998 Mar;13(3):744-8.
  • Benn PA, Fang M, Egan JF, Horne D, Collins R. Incorporation of inhibin-A in second-trimester screening for Down syndrome. Obstet Gynecol. 2003 Mar;101(3):451-4.
  • Arben Paralloi and Dr. Celia De Lozier. Second Trimester Maternal Screening Programs for the Detection of Down’s Syndrome. Geneva Foundation for Medical Education and Research.